According to
official figures more than one-third of adults in the US are now obese. The
obesity rate among American adults has approached 35%. A new weight-loss
drug Qsymia has been approved by the US Food and Drug Administration
(FDA). The approvals are the first in the US for 13 years.
FDA had already approved another anti-obesity drug Belvig last month. Qsymia is a combination of drugs phentermine and topiramate which has been already approved by the FDA and is marketed for aiding weight loss and preventing seizures. Qsymia is recommended for patients who are overweight or obese and have at least one other weight-related condition. The findings from two studies showed an average weight loss of 6.7% and 8.9% among patients who took Qsymia, along with dietary changes and exercise.
FDA had already approved another anti-obesity drug Belvig last month. Qsymia is a combination of drugs phentermine and topiramate which has been already approved by the FDA and is marketed for aiding weight loss and preventing seizures. Qsymia is recommended for patients who are overweight or obese and have at least one other weight-related condition. The findings from two studies showed an average weight loss of 6.7% and 8.9% among patients who took Qsymia, along with dietary changes and exercise.
The drug is not
recommended for pregnant women as it may harm fetuses. The drug is also not
recommended for patients with heart disease or who have recently suffered a
stroke because the drug can increase heart rate. Further trials are needed to
assess the impact of the drug on cardiac health.
No comments:
Post a Comment